Aldosterone and Cardiovascular Disease

Current Problems in Cardiology

Volumn 34, Issue 2, 2009, Pages 51-84

  Gaddam, Krishna K ^a   Pimenta, Eduardo ^a   Husain, Saima ^a   Calhoun, David A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; AMILORIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPLERENONE; FLUDROCORTISONE; SPIRONOLACTONE; VALSARTAN;

ADD ON THERAPY; ADRENALECTOMY; ARTICLE; ATHEROSCLEROSIS; BREAST TENDERNESS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONGESTIVE HEART FAILURE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; ENDOTHELIAL DYSFUNCTION; ERECTILE DYSFUNCTION; FIBROSIS; GYNECOMASTIA; HEART FAILURE; HEART HEMODYNAMICS; HEART INFARCTION; HORMONE ACTION; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; INFLAMMATION; KIDNEY DISEASE; KIDNEY FUNCTION; LOW DRUG DOSE; MENSTRUAL IRREGULARITY; MORBIDITY; MORTALITY; NONHUMAN; PATHOGENESIS; PREVALENCE; PRIMARY HYPERALDOSTERONISM; PROGNOSIS; RECOMMENDED DRUG DOSE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SALT INTAKE;

ADRENALECTOMY; ALDOSTERONE; ALDOSTERONE ANTAGONISTS; ANIMALS; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; HEART FAILURE; HUMANS; HYPERALDOSTERONISM; HYPERTENSION; KIDNEY DISEASES; METABOLIC SYNDROME X; TREATMENT OUTCOME;

EID: 58149165339     PISSN: 01462806     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cpcardiol.2008.10.002     Document Type: Article

References (74)

1. Tait J.F., Simpson S.A., and Grundy H.M. The effect of adrenal extract on mineral metabolism. Lancet 1 (1952) 122-124
2. Simpson S.A., Tait J.F., and Bush I.E. Secretion of a salt-retaining hormone by the mammalian adrenal cortex. Lancet 2 (1952) 226-228
3. Conn J.W. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med 45 (1955) 6-17
4. Fardella C.E., Mosso L., Gomez-Sanchez C., et al. Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab 85 (2000) 1863-1867
5. Lim P.O., Dow E., Brennan G., et al. High prevalence of primary aldosteronism in the Tayside hypertension clinic population. J Hum Hypertens 14 (2000) 311-315
6. Mosso L., Carvajal C., Gonzalez A., et al. Primary aldosteronism and hypertensive disease. Hypertension 42 (2003) 161-165
7. Schwartz G.L., and Turner S.T. Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity. Clin Chem 51 (2005) 386-394
8. Gallay B.J., Ahmad S., Xu L., et al. Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. Am J Kidney Dis 37 (2001) 699-705
9. Calhoun D.A., Nishizaka M.K., Zaman M.A., et al. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 40 (2002) 892-896
10. Strauch B., Zelinka T., Hampf M., et al. Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region. J Hum Hypertens 17 (2003) 349-352
11. Eide I.K., Torjesen P.A., Drolsum A., et al. Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens 22 (2004) 2217-2226
12. Umpierrez G.E., Cantey P., Smiley D., et al. Primary aldosteronism in diabetic subjects with resistant hypertension. Diabetes Care 30 (2007) 1699-1703
13. Naray-Fejes-Toth A., and Fejes-Toth G. The sgk, an aldosterone-induced gene in mineralocorticoid target cells, regulates the epithelial sodium channel. Kidney Int 57 (2000) 1290-1294
14. Funder J.W. Aldosterone and mineralocorticoids. In: Oparil S., and Weber M.A. (Eds). Hypertension, A Companion to Brenner and Rector's The Kidney. 2nd edition (2005), Elsevier, Philadelphia, PA 117-122
15. Brilla C.G., Prick R., Tan L.B., et al. Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res 67 (1990) 1355-1364
16. Brilla C.G., and Weber K.T. Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med 120 (1992) 893-901
17. Young M., Fullerton M., Dilley R., et al. Mineralocorticoids, hypertension, and cardiac fibrosis. J Clin Invest 93 (1994) 2578-2583
18. Rocha R., Martin-Berger C.L., Yang P., et al. Slective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology 143 (2002) 4828-4836
19. Stowasser M. New perspectives on the role of aldosterone excess in cardiovascular disease. Clin Exp Pharmacol Physiol 28 10 (2001) 783-791 [Review]
20. Ikeda U., Kanbe T., Nakayama I., et al. Aldosterone inhibits nitric oxide synthesis in rat vascular smooth muscle cells induced by interleukin-1 beta. Eur J Pharmacol 290 (1995) 69-73
21. Bauersachs J., Heck M., Fraccarollo D., et al. Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction: role of vascular superoxide anion formation and endothelial nitric oxide synthase expression. J Am Coll Cardiol 39 (2002) 351-358
22. Rajagopalan S., Duquaine D., King S., et al. Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation 105 (2002) 2212-2216
23. Blacher J., Amah G., Girerd X., et al. Association between increased plasma levels of aldosterone and decreased systemic arterial compliance in subjects with essential hypertension. Am J Hypertens 10 (1997) 1326-1334
24. Duprez D.A., De Buyzere M.L., Rietzschel E.R., et al. Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients. Eur Heart J 19 (1998) 1371-1376
25. Taddei S., Virdis A., Mattei P., et al. Vasodilation to acetylcholine in primary and secondary forms of human hypertension. Hypertension 21 (1993) 929-933
26. Farquharson C.A., and Struthers A.D. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 101 (2000) 594-597
27. Nishizaka M.K., Zaman M.A., Green S.A., et al. Impaired endothelium-dependant flow mediated vasodilation in hypertensive subjects with hyperaldosteronism. Circulation 109 (2004) 2857-2861
28. Gokce N., Keaney Jr. J.F., Hunter L.M., et al. Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease. J Am Coll Cardiol 41 (2003) 1769-1775
29. Genest J., Lemieux G., Davignon A., et al. Human arterial hypertension: a state of mild chronic hyperaldosteronism?. Science 123 (1956) 503-505
30. Vasan R.S., Evans J.C., and Larson M.G. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med 351 (2004) 33-41
31. Newton-Cheh C., Guo C.Y., Gona P., et al. Clinical and genetic correlates of aldosterone-to-renin ratio and relations to blood pressure in a community sample. Hypertension 49 (2007) 846-856
32. Grim C.E., Cowley Jr. A.W., Hamet P., et al. Hypertension and hypertension: ethnic differences. Hypertension 45 (2005) 766-772
33. Conn J.W., Cohen E.L., Rovner D.R., et al. Normokalemic primary aldosteronism: a detectable cause of curable "essential" hypertension. JAMA 193 (1965) 200-206
34. Fishman L.M., Kuchel O., Liddle G.W., et al. Incidence of primary aldosteronism uncomplicated "essential" hypertension. A prospective study with elevated aldosterone secretion and suppressed plasma renin activity used as diagnostic criteria. JAMA 205 (1968) 497-502
35. Gordon R.D., Ziesak M.D., Tunny T.J., et al. Evidence that primary aldosteronism may not be uncommon: 12% incidence among antihypertensive drug trial volunteers. Clin Exp Pharmacol Physiol 20 5 (1993) 296-298
36. Gordon R.D., Stowasser M., Tunny T.J., et al. High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol 21 (1994) 315-318
37. Sartori M., Calo L.A., Mascagna V., et al. Aldosterone and refractory hypertension: a prospective cohort study. Am J Hypertens 19 (2006) 373-379
38. Ouzan J., Perault C., Lincoff A.M., et al. The role of spironolactone in the treatment of patients with refractory hypertension. Am J Hypertens 1 (2002) 333-339
39. Nishizaka M.K., Zaman M.A., and Calhoun D.A. Efficacy of low dose spironolactone in subjects with resistant hypertension. Am J Hypertens 16 (2003) 925-930
40. Mahmud A., Mahgoub M., Hall M., et al. Does aldosterone-to-renin ratio predict the antihypertensive effect of the aldosterone antagonist spironolactone?. Am J Hypertens 18 (2005) 1631-1635
41. Chapman N., Dobson J., Wilson S., et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 49 (2007) 839-845
42. Saha C., Eckert G.J., Amrosius W.T., et al. Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension. Hypertension 46 (2005) 481-487
43. Engeli S., Böhnke J., Gorzelniak K., et al. Weight loss and the renin-angiotensin-aldosterone system. Hypertension 45 (2005) 356-362
44. Goodfriend T.L., Ball D.L., and Gardner H.W. An oxidized derivative of linoleic acid affects aldosterone secretion by adrenal cells in vitro. Prostaglandins Leukot Essent Fatty Acids 67 (2002) 163-167
45. Ehrhart-Bornstein M., Lamounier-Zepter V., Schraven A., et al. Human adipocytes secrete mineralocorticoid-releasing factors. Proc Natl Acad Sci USA 100 (2003) 14211-14216
46. Calhoun D.A., Nishizaka M.K., Zaman M.A., et al. Aldosterone excretion among subjects with resistant hypertension and symptoms of sleep apnea. Chest 25 (2004) 112-117
47. Nishizaka M.K., Pratt-Ubunama M., Zaman M.A., et al. Validity of plasma aldosterone-to-renin activity ratio in African American and white subjects with resistant hypertension. Am J Hypertens 18 (2005) 805-812
48. Rossi G.P., Bernini G., Caliumi C., et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 48 (2006) 2293-2300
49. Nwariaku F.E., Miller B.S., Auchus R., et al. Primary hyperaldosteronism: effect of adrenal vein sampling on surgical outcome. Arch Surg 141 (2006) 497-503
50. Swedberg K., Eneroth P., Kjekshus J., et al. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation 82 (1990) 1730-1736
51. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341 (1999) 709-717
52. Pitt B., Remme W., Zannad F., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 (2003) 1309-1321
53. Juurlink D.N., Mamdani M.M., Lee D.S., et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351 (2004) 543-551
54. Beygui F., Collet J.P., Benoliel J.J., et al. High plasma aldosterone levels on admission are associated with death in patients presenting with acute ST-elevation myocardial infarction. Circulation 114 (2006) 2604-2610
55. Rocha R., Chander P.N., Khanna K., et al. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 31 (1998) 451-458
56. Conn J.W., Knopf R.F., and Nesbit R.M. Clinical characteristics of primary aldosteronism from an analysis of 145 cases. Am J Surg 107 (1964) 159-172
57. Irie F., Iso H., Sairenchi T., et al. The relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population. Kidney Int 69 (2006) 1264-1271
58. Tonelli M., Jose P., Curhan G., et al., Cholesterol and Recurrent Events (CARE) Trial Investigators. Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomised trial. BMJ 332 (2006) 1426-1429
59. Fox C.S., Larson M.G., Hwang S.-J., et al. Cross-sectional relations of serum aldosterone and urine sodium excretion to urinary albumin excretion in a community-based sample. Kidney Int 69 (2006) 2064-2069
60. Rossi G.P., Bernini G., Desideri G., et al., PAPY Study Participants. Renal damage in primary aldosteronism: results of the PAPY study. Hypertension 48 (2006) 232-238
61. Halimi J.M., and Mimran A. Albuminuria in untreated patients with primary aldosteronism or essential hypertension. J Hypertens 13 (1995) 1801-1802
62. Sechi L.A., Novello M., Lapenna R., et al. Long-term renal outcomes in patients with primary aldosteronism. JAMA 295 (2006) 2638-2645
63. Ribstein J., Cilar G.D., Fesler P., et al. Relative glomerular hyperfiltration in primary aldosteronism. J Am Soc Nephrol 16 (2005) 1320-1325
64. Pimenta E., and Calhoun D. Aldosterone, dietary salt, and renal disease. Hypertension 48 (2006) 209-210
65. Epstein M. Aldosterone blockade: an emerging strategy for abrogating progressive renal disease. Am J Med 119 (2006) 912-919
66. van den Meiracker A.H., Baggen R.G., Pauli S., et al. Spironolactone in type 2 diabetic nephropathy: effects on proteinuria, blood pressure and renal function. J Hypertens 24 (2006) 2285-2292
67. Schjoedt K.J., Rossing K., Juhl T.R., et al. Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int 68 (2005) 2829-2836
68. Epstein M., Williams G.H., Weinberger M., et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 1 (2006) 940-951
69. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106 (2002) 3143-3421
70. Bochud M., Nussberger J., Bovet P., et al. Plasma aldosterone is independently associated with the metabolic syndrome. Hypertension 48 (2006) 239-245
71. Kidambi S., Kotchen J.M., Grim C.E., et al. Association of adrenal steroids with hypertension and the metabolic syndrome in blacks. Hypertension 49 (2007) 704-711
72. Fallo F., Veglio F., Bertello C., et al. Prevalence and charecteristics of the metabolic syndrome in primary aldosteronism. J Clin Endocrinol Metab 91 (2006) 454-459
73. Fallo F., Della Mea P., Sonino N., et al. Adiponectin and insulin sensitivity in primary aldosteronism. Am J Hypertens 20 (2007) 855-861
74. Milliez P., Girerd X., Plouin P.F., et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 45 (2005) 1243-1248